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Abstract: An efficient, five-step synthetic approach to various acyclic 1,3-diamines
has been developed and applied to the preparation of a novel class of open-chained
fentanyl analogues. The acyclic derivatives 5.1–5.5 (all new compounds) were syn-
thesized with the aim of estimating the significance of the piperidine ring for the
opioid analgesic activity of anilido-piperidines. The starting -keto-amide 1.1, pre-
pared by the aminolysis of methyl acetoacetate with methylphenethylamine, (93 %
yield), was successively reacted with NaH and BuLi, to form the highly reactive
,-dienolate anion 1.1a. Regio and chemoselective -alkylation of the dienolate
with various primary and secondary alkyl halides furnished the -keto-amides
1.2–1.5 (76–91 %). Reductive amination of the keto-amides 1.1–1.5 with aniline
and Zn powder in acetic acid, via the enamine intermediates 2.1–2.5, afforded the
-anilino amides 3.1–3.5 (74–85 %). After reductive deoxygenation of the tertiary
amide group, using in situ generated diborane, the corresponding 1,3-diamines
4.1–4.5 were obtained (87–97 %). The synthesis of ()-2,3-seco-fentanyls 5.1–5.5
was completed by N-acylation of the diamines 4.1–4.5 with propionyl chloride, fol-
lowed by precipitation of the monooxalate salts (86–95 %). The parent compound,
2,3-seco-fentanyl 5.1, was found to be a 40 times less potent narcotic analgesic than
fentanyl but still 5–6 times more active than morphine in rats, while i-Pr derivative
5.3 was inactive. Apart from the pharmacological significance, the general proce-
dure described herein may afford various functionalized, 1,3-diamines as potential
complexing agents and building blocks for the synthesis of aza-crown ethers.
Keywords: open-chain fentanyl analogues, 1,3-diamines, opioid analgesics.
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INTRODUCTION
Analgesics are widely used to treat mild to severe pain of various origins.1 They
are generally divided into two broad groups: anti-inflammatory agents (steroid and
non-steroid) and opioid analgesics acting upon the specific opioid receptors (, , )
in the central nervous system and other tissues.
2 Morphine I,3 a natural product and a
major constituent of opium,3 is certainly the best known representative of the later
class, having been used to alleviate pain for millennia (originally as opium, then as
the pure compound). However, its highly adverse effects, such as acute, life threating
respiratory depression and chronic development of tolerance and addiction, led to ef-
forts towards the synthesis of novel drugs with better pharmacological profiles.4,5
Initially, the morphine molecule itself was modified via numerous partial syntheses,
followed by the more complex total synthesis of various morphine-like compounds,
generally known as opioids.5 A number of novel classes of compounds, often struc-
turally dissimilar to morphine, were found to possess high and clinically useful
opioid analgesic activity. Those include5 (Scheme 1) morphinans3 (e.g., levorphanol
II),3 benzomorphans3 (e.g., phenazocine III),3 meperidines (e.g., meperidine IV),3
anilido-piperidines (gen. structure V, e.g., fentanyl VI),3,6 open-chain compounds
(e.g., diampromide VII,3 methadone VIII),3 synthetic opioid peptides5 (related to
the endogenous opioid peptides, natural ligands of opioid receptors) and many oth-
ers.5 Research efforts in the field of opioid analgesics and analgesia in general,
continue unabated, as evidenced by the plethora of recent papers and patents.7
Except for the opioid peptides, the great majority of the synthetic opioids pos-
sess a piperidine (or rarely a pyrrolidine) ring and a basic nitrogen, known to be es-
956 IVANOVI] et al.
Scheme 1.
sential for opioid activity.5 Surprisingly, only a few open-chain derivatives, such as
diampromide or methadone, have been synthesized. Although diampromide may
be considered as an open-chain fentanyl analogue, structurally it is 1,2-diamine,
unlike 1,3-diamines resulting from the scission of the pipeiridine ring.
In view of the fact that anilido-piperidines (fentanyl and its derivatives) are
highly potent opioids (100–1000  morphine), the synthesis of exact open-chain
fentanyl analogues,
8 (2,3-seco-fentanyls) was envisaged in order to estimate the
importance of the piperidine ring for opioid activity.
RESULTS AND DISCUSSION
The synthetic approach to seco-fentanyl analogues is outlined in Scheme 2.
The starting keto-amide 1.1 was prepared by aminolysis of methyl ace-
toacetate with methylphenethylamine at 	 150 ºC. Esters of malonic acid and
-keto esters are known to undergo aminolysis much easier than simple esters, ei-
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Scheme 2.
ther thermally or catalyzed by 4-dimethylaminopyridine (DMAP).
9 However, at
lower temperatures (20–100 ºC), -keto esters readily form stable conjugated
enamines, especially in the presence of acid catalysts.
10 We also observed rapid
enamine formation (by TLC and IR), when the aminolysis was attempted in vari-
ous solvents (MeOH, i-PrOH, CH2Cl, PhMe, xylene). On the contrary, the ami-
nolysis proceeded smoothly in the absence of solvent, (	2 eq. of methyl ace-
toacetate) at > 150 ºC and it was accelerated by the continuous removal of the
formed MeOH. Further rate acceleration (2–3 times) was observed in the presence
of basic catalyst (0.5 mol% MeONa). Thus, the keto-amide 1.1 was obtained
within 	 15–20 min (93 % crude yield), while sterically more hindered amines,
N-ethyl-2-phenethylamine and N,N-bis(2-phenylethyl)amine, required longer re-
action times (60–120 min) and gave lower isolated yields (60–75 %). The latter
two amides were not used further for the synthesis. In all instances, the formation
of various side products was observed (	5–25 % by TLC and GC). An alternative
method to synthesize -keto amides, by low temperature acylation of tertiary am-
ide enolates, has been reported.
11 Although of considerable scope, it is operation-
ally inconvenient and give slower yield (	50 %).
In the next step, 1.1 was selectively -alkylated with various alkyl halides, to
afford 4-alkyl keto amides 1.2–1.5. The conversion was affected via the ,-enola-
te dianion 1.1a, prepared by the literature procedure for bis-metalation of -keto
esters
12 and -keto amides.13 First, the -monoenolate was generated using NaH
(1.2 eq., THF, 30 ºC, 30 min), which was then reacted with BuLi (1.6 M, 1.05 eq., 0
ºC, 30 min), to form the orange-red dienolate 1.1a solution. No addition products
of BuLi (alcohols) were detected upon quenching with H2O or MeOH. The dieno-
late 1.1a is also thermally stable: after 5 h at 30 ºC, only the starting compound 1.1
was isolated after quenching. However, its high nucleophilicity permits its very ra-
pid reaction with primary alkyl halides (chlorides, bromides, iodides) and i-Prl
(15–30 min, 0–30 ºC, exothermal reaction), leading to colour discharge and the pre-
cipitation of the halide salts. The alkylation is exclusively -regioselective, with nei-
ther -alkylated nor bis-alkylated products detected. It is also highly chemoselective
(no significant side products were detected), affording the keto-amides 1.2–1.5 in
76–91 % yields, after purification. Significantly, i-Prl as alkylating agent gave no
elimination product. Although it was found to be possible to a affect a consecutive
-alkylation, using excess of the alkylating reagent, (at 	 50 ºC), this possibility
was not studied further. All the prepared keto-amides (1.1–1.5) exhibit distinct car-
bonyl bands in their IR spectra (1720, 1640 cm–1), M+1 peaks (100 % in chemical
ionisation MS) and were homogeneous by TLC and cap. GC (pyrity >95 %). The
1H-NMR and 13C-NMR spectra display extensive rotatory isomerism, as a result
of constrained rotation around the (C=O)–N bond. The effect is significantly more
pronounced compared to simple amides, since the -keto group additionally rigi-
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difies the system (Scheme 3). Almost all the signals in the
13C-NMR spectra were
doublets, separated by 	0.5–2 ppm (see Experimental Section). In addition, the
probable presence of enolic forms in low concentration could be inferred from the
1H-NMR spectra (	5.0 , s, vinyl H; 	15 , s, enol OH).
Keto-amides 1.1–1.5 were converted into the corresponding -anilino-amides
3.1–3.5 using aniline and Zn powder in acetic acid, according to a reductive amination
procedure published earlier.14 The optimal yields (74–85 % of the purified products)
were obtained at 	20 ºC after 24–48 h, while heating mainly gave stable conjugated
enamines 2.1–2.5 and acetanilide.15 The slow step in the process is enamine reduction,
as enamine formation is rapid under the reaction conditions according to TLC and IR
and they are readily isolatable. In the case of keto-amides 1.3 and 1.5, complete reduc-
tion could not be achieved, due to steric hindrance (	10–20 % of the corresponding
enamines remained unreacted). After completion of the reduction (as evidenced by
TLC and IR), the excess aniline was quantitatively converted into acetanilide by
briefly heating the mixture (	 90 ºC, 1h). Under these conditions, the secondary amino
group of the anilino-amides 3.1–3.5 did not undergo acetylation to any extent. After
workup with aq. NH4OH, to prevent precipitation of gelatinous Zn(OH)2, the isolated
products were precipitated as oxalate salts. An attempted direct reductive amination of
keto-amide 1.1 with NaBH3CN (MeOH, solid NaH2PO4 or Et3N/AcOH, pH 5–7), re-
sulted in extensive reduction of the carbonyl group. However, preforming the enamine
2.1 (PhMe, cat. TsOH, aniline, water separation) and its reduction with NaBH3CN, in
two separate steps, cleanly furnished the -anilino amide 3.1. Spectral data confirmed
the structures and purity: IR (carbonyl band at 1630 cm–1), MS (CI, M+1 peaks 100
%), GC (purity > 95 %). However, rotatory isomerism in the 1H-NMR and 13C-NMR
spectra was observed again, albeit to a lower extent. Thus, the observed 13C-NMR sig-
nal separation of the rotatory isomers was 	0.1–1 ppm (see Experimental).
The purified anilino-amides 3.1–3.5 were reductively deoxygenated to the
diamines 4.1–4.5 using in situ generated diborane (NaBH4, BF3
.Et2O, in THF) ac-
cording to a known procedure for nitrile reduction.16 We observed a rapid and
quantitative reduction of the amide group (0.65 ºC, 2 h), with a BH3 to amide mole
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ratio of 	4:1. A considerable excess of borane is necessary for complete reduction,
as it forms a stable complex with the amino function of anilino-amides 3.1–3.5.
Similarly, the reduction products – diamines 4.1–4.5 – were obtained as stable
complexes with at least two BH3 molecules, requiring decomposition with boiling
HCl. No side products were detected in the free bases (TLC, cap. GC, 1H-NMR
13C–NMR) (see Experimental). As expected evidence of rotatory isomerism was
absent in the 1H-NMR and 13C-NMR spectra.
The synthesis of 2,3-seco-fentanyl analogues was completed by N-acylation
of the diamines 4.1–4.5 with propionyl chloride in CH2Cl2. Although the mole-
cules possess a tertiary amino function which binds the liberated HCl, the addition
of 	0.3 eq. of triethylamine was found necessary for quantitative acylation. The
only detected contaminants were neutral compounds, formed by decomposition of
the propionyl chloride under the reaction conditions. The anilides 5.1–5.5, ob-
tained in near quantitative yields, were purified as monooxalate salts. Spectral data
of the free bases fully confirmed the proposed structures (see Experimental).
Two of the synthesised derivatives, 5.1 monooxalate (2,3-seco-fentanyl, the
parent compound) and 5.3 monooxalate (i-Pr analogue), were tested pharmacolog-
ically for analgesic (antinociceptive) activity, using tail-immersion test in rats17
and compared to fentanyl citrate as a standard. All three compounds were adminis-
tered intraperitoneally. At least three doses of each compound were tested with 6–8
rats per dose. The dose-response curves were analysed using linear regression. The
ED50 (dose effective upon 50 % of the tested animals) and 95 % confidence limits
were estimated from the dose-response curve by using standard statistical soft-
ware.18 The present experiments revealed that 5.1 is about 40 times less potent
than fentanyl with an ED50 (95 % confidence limits) values: 0.45 (0.19–1.03)
mg/kg (5.1 free base) and 0.0104 (0.006–0.018) mg/kg (fentanyl free base). Also,
the ED99 of 5.1 exhibited significantly (p < 0.05) shorter duration of action (up to
30 min) in comparison to the equi-effective dose of fentanyl (up to 50 min). The
antinociceptive effect of 5.1 was antagonized by the specific opioid antagonist,
naloxone hydrochloride (0.025 mg/kg, s.c.), thus confirming the mechanism of ac-
tion is indeed via the iopioid receptors. The other derivative, 5.3 monooxalate was
found to be completely inactive.
The finding that a direct open-chained fentanyl analogue such as 2,3-seco-fen-
tanyl is much less potent than fentanyl, generally suggests the influence of the
steric factor upon the antinociceptive activity, and in particular, the significance of
the piperidine ring as a pharmacophore. However, some acyclic systems may re-
tain a very considerable analgesic potency (5.1 is 	5 times more potent than mor-
phine in rats) indicating that a ring system (piperidine or other) is not essential for
ligand-receptor binding. Rather, it seems that the piperidine ring, due to its rela-
tively rigid conformation, serves mainly to enhance the ligand-receptor binding,
amplifying the analgesic activity some 40 times.
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Detailed pharmacological study of the open-chained fentanyl analogues will
be published elsewhere.
Apart from the pharmacological significance, the synthetic approach dis-
closed in this paper may be applied to the synthesis of various 1,3-diamines as po-
tential complexing agents and building blocks for the synthesis of aza-crown
ethers. It is noteworthy that the synthesis could be readily extended, by several ad-
ditional alkylation steps in the - and/or -position of the keto-amides, thus permit-
ting the construction of elaborate intermediates. A recent finding that the otherwise
stable borane-amine complexes are quantitatively cleaved by a mild, catalytic pro-
cess (MeOH, 10 % Pd/C or NaNi, r.t., 0.1–20 h) allows for the presence of
acid-sensitive groups such as acetals, –CO2t–Bu, –OMOM, –OTHP or OTBS.
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Furthermore, aliphatic amines may be used in the reductive amination step, pro-
vided that the enamines are formed first, followed by NaBH3CH reduction.
6j
EXPERIMENTAL
IR Spectra were recorded on a Perkin-Elmer FT IR 1725X instrument, at 4 cm-1 resolution.
1H-NMR and 13C-NMR were recorded on a Varian Gemini spectrometer, at 200 MHz and 50 MHz
respectively, using CDCl3 as the solvent and TMS as the internal standard. (Insufficient resolution
of some 1H-NMR spectra precluded precise integration of the multiplets, hence the number of the
corresponding hydrogens could not be determined. In these instances, only approximate multiplet
intervals are reported). Mass spectra were recorded on a Finigan-Math instrument, model 8230, em-
ploying both the electron impact (70 eV) and chemical ionisation (with i-butane) techniques. Gas
chromatograms were obtained on a Varian 3400 instrument with an FID detector, on a nonpolar
DB-5 column (5 m). MeOH, i-PrOH, Et2O, THF, EtOAc, PhMe, hexane and CH2Cl2 were of p.a.
grade and purified further according to standard procedures. Absolute THF and Et2O were prepared
by distillation from benzophenone/sodium. Reagents were of p.a. grade and used as supplied
(Aldrich Chemical Co., Merck Darmstadt Chemical Co. and Fluka Chemical Co.). Dry flash chro-
matography was performed on SiO2 12–26  or 10–18 , ICN Pharmaceutical. Magnetic stirring
was used in all experiments.
1. N-methyl-3-oxo-N-phenethylbutanamide (1.1). A one necked, round bottomed flask fitted
with a pressure equalizing dropping funnel to which a reflux condenser with a CaCl2 drying tube
was mounted was purged with Ar and the flask is charged with methyl acetoacetate (25.0 mL, 0.23
mol) and solid MeONa (0.1 g) while methyl-phenethyl amine (16.2 g, 0.12 mol) was added to the
dropping funnel. The contents of the flask were stirred magnetically and heated to 	160 ºC (oil
bath), then the amine was added dropwise over 5 min. The rapid evolution of MeOH started immedi-
ately. The dropping funnel stopcock was closed after 5 min and the liberated MeOH was distilled
into the dropping funnel through the side arm. After ceasation of the distillation (	 5 min), the reac-
tion mixture was cooled (20 ºC), neutralized with solid NH4Cl (200 mg), and the excess methyl
acetoacetate removed (at 	 20 Torr). The residue was distilled. Yield: 24.4 g (93 %), pale yellow,
viscous oil, b.p. 120–125 ºC/0.1 Torr; purity (cap. GC): 95 %. Further purification by dry flash chro-
matography (15 g SiO2/1 g substance), using hexane/EtOAc gradient (95:5, 90:10, etc.), yields ana-
lytical sample; purity (cap. GC): 98 %.
IR (cm-1): (characteristic bands) 1722, 1642. 13C-NMR (ppm): 
2 rotamers 21.89, 30.03,
33.34, 33.47, 34.43, 36.49, 49.22, 49.76, 50.27, 52.09, 126.34, 126.85, 128.14, 128.45, 128.76,
137.90, 138.74, 166.43, 166.65, 202.44, 202.70. MS (CI): 220 (M+1, 100 %).
A typical procedure for -alkylation of keto-amide 1.1 is illustrated for keto-amide 1.3.
2. N,5-dimetyl-3-oxo-N-phenethylhexanamide (1.3). A round-bottomed flask (100 mL) was
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fitted with a thermometer and pressure-equalizing dropping funnel connected to an oil bubblier
through a septum. The system was purged with Ar and the flask charged with THF (40 mL) and NaH
(60 %, 0.80 g, 11 mmol). A solution of keto-amide 1.1 (2.2 g, 10 mmol/5 mL THF) was added
dropwise over 5 min, (H2 evolution) and the stirring continued for 15 min at r.t. The homogeneous
solution was cooled to 0 ºC, BuLi (2M/cyclohexane, 12.1 mmol, 6.1 mL) was injected into the drop-
ping funnel and added dropwise over 10 min. The resulting orange-red solution was stirred for a fur-
ther 15 min (0 ºC), then i-Prl (2.05 g, 12 mmol/5 mL THF) was injected into the dropping funnel and
added over 10 min (0 ºC). The solution soon became colourless and a white precipitate formed
(Nal). Stirring was continued for 1 h (	20 ºC), the mixture was concentrated (rotatory evaporator),
H2O (50 mL) was added and the resulting emulsion extracted with CH2Cl2 ( 2  30 mL). After dry-
ing (anh. MgSO4), filtration and solvent removal, the crude keto-amide 1.3 was obtained as a yel-
low-brown viscous oil, slightly contaminated with the starting keto-amide 1.1 and some impurities
(GC purity 	93 %). After dry flash chromatographic purification (	40 g SiO2), using a hex-
ane/EtOAc gradient (95:5, 90:10, etc.), pure 1.3 was obtained as a pale yellow viscous oil. Yield: 2.0
g (76 %); purity (cap. GC) 	99 %.
IR (cm-1): (characteristic bands) 1722, 1642. 1H-NMR (): 
2 rotamers + enol form 0.89 (d, J
= 7.6, CH3), 0.92 (d, J = 7.6, CH3), 2.00–2.22 (m), 2.31 (d, J = 6.6), 2.41 (J = 6.8), 2.82–2.89 (m),
2.86 (s, N–CH3), 2.98 (s, N–CH3), 3.14 (s, CH2), 3.48 (t, J = 6.8), 3.59 (d, J = 7.8), 3.62 (d, J = 9.0),
5.0–5.08 (m, enol form, vinyl H), 7.08–7.32 (m, 5HAr), 14.75 (d, J = 32, enol OH).
13C-NMR (ppm):

2 rotamers s 21.74, 23.43, 23.48, 32.58, 32.86, 33.80, 35.77, 44.46, 48.03, 49.03, 49.10, 50.91,
51.39, 86.70, 125.68, 126.15, 127.82, 128.13, 128.17, 128.21, 137.56, 138.32, 166.09, 166.24,
171.26, 176.36, 176.82, 203.46, 203.67. MS (CI): 262 (M+1, 100 %), 523 (2M+1, 60 %).
The above procedure was used to synthesize the keto-amides 1.2, 1.4 and 1.5.
3. N-methyl-3-oxo-N-phenethyloctanamide (1.2). Scale 15 mmol; yield: 3.75 g (91 %); pale yel-
low viscous oil; purity (cap. GC, not purified by chromatography): 96 %. Alkyl halide: butyl bromide.
IR (cm-1): (characteristic bands) 1722, 1642. 1H-NMR ():
2 rotamers + enol form 0.84–0.92
(m), 1.22–1.35 (m), 1.44–1.62 (m), 2.42 (t, J = 7.4, CH2), 2.52 (t, J = 7.2, CH2), 2.81–2.93 (m), 2.87
(s, N–CH3), 2.98 (s, N–CH3), 3.16 (s, CH2), 3.48 (d, J = 10.4, CH), 3.50 (d, J = 7.2, CH), 3.59 (d, J =
7.8), 3.62 (d, J = 9.0, CH), 5.0–5.08 (m, enolic form, vinyl H), 7.12–7.20 (m, 5HAr).
13C-NMR
(ppm): 
2 rotamers 13.09, 21.59, 22.28, 25.37, 30.34, 30.47, 32.40, 32.67, 33.61, 35.59, 41.91,
47.35, 48.23, 48.93, 51.25, 85.55, 125.50, 125.95, 127.64, 127.95, 128.01, 128.07, 137.44, 138.15,
166.23, 166.32, 171.18, 203.75, 203.95. MS(CI): 275 (M+1, 100 %), 551 (2M+1, 95 %).
4. N-methyl-3-oxo-N-phenethyl-5-phenylpentanamide (1.4). Scale: 10 mmol; yield: 2.69 g (87
%); pale yellow viscous oil; purity (cap. GC after chromatography): 99 %. Alkyl halide: benzyl
chloride.
IR (cm-1): (characteristic bands) 1722, 1642. 1H-NMR (): 
2 rotamers + enol form 2.66–2.91
(m), 2.78 (s, N–CH3), 2.95 (s, N–CH3), 3.11 (s, CH2), 3.40 (t, J = 7.0), 3.46 (s), 3.56 (d, J = 7.6), 3.59
(d, J = 9.0), 4.96 (d, J = 19, enol form, vinyl H), 7.06–7.36 (m, 10 HAr).
13C-NMR (ppm): 
2
rotamers 28.83, 32.02, 32.68, 32.90, 33.77, 35.75, 43.45, 43.53, 47.87, 48.81, 49.11, 51.37, 86.32,
125.54, 125.79, 126.09, 126.25, 127.80, 127.84, 127.89, 128.23, 137.55, 138.93, 140.21, 166.05,
166.18, 203.05, 203.20. MS (CI): 319 (M+1, 100 %), 619 (2M+1, 30 %).
5. N-methyl-3-oxo-N-phenethyl-6-phenylhexanamide (1.5). Scale: 10 mmol; yield: 2.65 g (82
%); pale yellow viscous oil; purity (cap. GC after chromatography): 99 %. Akyl halide: phenethyl
bromide.
IR (cm-1): (characteristic bands) 1722, 1642. 1H-NMR (): 
2 rotamers + enol form 1.82–1.95 (m),
2.40–2.50 (m), 2.54–2.66 (m), 2.79–2.91 (m), 2.84 (s, N–CH3), 2.97 (s, N–CH3), 3.11 (s, CH2), 3.46 (t, J
= 7.0), 3.60 (t, J = 8.0), 5.01–5.08 (br. d, J = 14, enolic form, vinyl H), 7.05–7.38 (m, Ar). 13C-NMR
(ppm): 
2 rotamers 24.33, 32.65, 32.89, 33.80, 34.25, 34.54, 35.80, 41.42, 47.56, 48.55, 49.09, 51.40,
125.34, 125.77, 126.23, 127.80, 127.89, 128.25, 137.57, 138.34, 141.01, 166.19, 166.36, 203.63,
203.83. MS (CI): 219 (M-104, 25 %), 324 (M+1, 100 %), 366 (M+43, 40 %), 647 (2M+1, 1 %).
962 IVANOVI] et al.
The typical procedure for the synthesis of the anilino-amides 3.1–3.5 is illustrated for
anilino-amide 3.3.
6. N,5-dimethyl-N-phenethyl-3-(phenylamino)hexanamide (3.3). A single-necked, round-bot-
tomed flask (25 mL) fitted with a reflux condenser was charged with the keto-amide 1.3 (1.31 g, 5.0
mmol), aniline (1.0 g, 11 mmol), activate Zn powder (2.0 g, 31 mmol) and AcOH (15 mL). The mix-
ture was stirred (48 h at 	20 ºC), then heated to 	90 ºC (1 h), cooled and added slowly into NH4OH
(25 %, 40–50 mL, pH 	 10). After extraction (CH2Cl2, 2  30 mL), washing with H2O (50 mL), dry-
ing (anh. K2CO3), filtration and solvent removal (rotatory evaporator), the crude product was ob-
tained as a reddish-brown viscous oil. It was a mixture of enamine 2.3, anilino-amide 3.3 and acetan-
ilide with Rf values (eluent hexane/EtOAc 7:3): 0.60, 0.35 and 0.1, respectively. After dry flash
chromatography (40 g SiO2) with a hexane/EtOAc gradient (99:5, 90:10, etc.) pure anilino-amide
3.3 was obtained. Yield: 1.25 g, (74 g); pale yellow viscous oil, purity (cap. GC) 	99 %.
IR (cm-1): (characteristic bands): 3342, 1632, 1602. 1H-NMR (): 
2 rotamers 0.88 (d, J = 6.6,
CH3), 0.90 (d, J = 6.6, CH3, 0.92 (d, J = 6.4, CH3), 0.94 (d, J = 6.6, CH3), 1.27–1.35 (m), 1.43–1.51
(m), 1.55–1.84 (m), 2.18 (d, J = 6.6), 2.30 (d, J = 4.4), 2.44 (d, J = 6.4), 2.50 (d, J = 4.4), 2.74–2.83
(m), 2.80 (s, N–CH3), 2.92 (s, N–CH3), 3.46 (td, Jd = 1.2, Jt = 8.2), 3.57 (td, Jd = 1.6, Jt = 8.0),
3.78–3.98 (m, CH2), 6.56–6.70 (m, 3HAr), 7.05–7.35 (m, 7HAr).
13C-NMR (ppm): 
2 rotamers
21.93, 22.03, 23.05, 24.86, 24.92, 33.11, 33.51, 34.55, 36.01, 36.83, 37.46, 44.42, 48.25, 48.34,
49.53, 51.26, 113.06, 116.84, 126.16, 126.63, 128.31, 128.62, 128.68, 129.20, 137.99, 138.97,
147.41, 171.04, 171.22. MS (CI): 339 (M+1, 100 %), 395 (M+57, 10 %).
The above procedure was used to synthesize the anilino-amides 3.1, 3.2, 3.4, 3.5 except that
the products were purified as oxalate salts (1.1 eq. of anh. oxalic acid in i-PrOH). The free bases
were liberated at pH > 12 (10 % aq. NaOH).
7. N-methyl-N-phenethyl-3-(phenylamino)butanamide 3.1. Scale: 15 mmol, yield: 3.78 g (85
%); pale yellow viscous oil, purity (cap. GC): 98 %.
IR (cm-1): (characteristic bands): 3342, 1632, 1602. 1H-NMR (): 
2 rotamers 1.13 (d, J = 5.8,
CH3), 1.26 (d, 6.0, CH3), 2.05–2.16 (m), 2.30–2.41 (m), 2.59 (dd, J1 = 4.2, J2 = 15.8), 2.75–2.86 (m),
2.81 (s, CH3), 2.93 (s, CH3), 3.46 (t, 7.4), 3.58 (td, Jd = 2, Jt = 7.2), 3.82–4.12 (m), 6.55–6.72 (m,
3HAr), 7.05–7.37 (m, 7HAr).
13C-NMR (ppm): 
2 rotamers 20.63, 20.72, 33.25, 33.56, 34.61, 36.09,
38.18, 38.97, 45.87, 49.02, 51.36, 113.39, 117.18, 126.23, 126.70, 128.40, 128.71, 129.22, 138.01,
138.97, 147.00, 170.93, 171.13. MS (CI): 297 (M+1, 100 %), 311 (M+14, 10 %), 353 (M+57, 5 %).
8. N-methyl-N-phenethyl-3-(phenylamino)octanamide (3.2). Scale: 10 mmol, yield: 2.91 g (83
%), pale yellow viscous oil, purity (cap. GC), 98 %.
IR (cm-1): (characteristic bands): 3342, 1632, 1602. 1H-NMR (): 
2 rotamers 0.84–0.87 (m),
1.26–1.62 (m), 2.09–2.20 (m), 2.28–2.59 (m), 2.73–2.82 (m), 2.79 (s, N–CH3), 2.91 (s, CH3),
3.41–3.48 (m), 3.52–3.60 (m), 3.72–3.87 (m), 6.55–6.69 (m, Ar), 7.07–7.32 (m, Ar). 13C-NMR
(ppm): 
2 rotamers 13.93, 22.49, 26.04, 31.65, 33.25, 33.54, 34.62, 35.09, 36.09, 36.64, 37.20,
49.62, 50.38, 51.36, 113.18, 116.91, 126.19, 126.67, 128.37, 128.67, 129.20, 138.01, 139.01,
139.01, 147.46, 171.09, 171.25. MS (CI): 353 (M+1, 100 %), 409 (M+57, 10 %).
9. N-methyl-N-phenethyl-5-phenyl-3-(phenylamino)pentanamide (3.4). Scale: 5.0 mmol, yield:
1.55 g, (80 %), pale yellow viscous oil, purity (cap. GC): 96 %
IR (cm-1): (characteristic bands): 3342, 1632, 1602. 1H-NMR (): 
2 rotamers 1.63–1.84 (m),
1.89–2.02 (m), 2.23 (dd, J1 = 4.0, J2 = 9.8), 2.47 (t, J = 5.8), 2.69–2.80 (m), 2.74 (s, N–CH3), 2.89 (s,
N–CH3), 3.40 (t, J = 7.2), 3.54 (t, J = 7.0, 3.69–3.89 (m), 3.91–4.18 (m), 6.52–6.69 (m, 3HAr),
7.04–7.36 (m, 7HAr).
13C-NMR (ppm): 
2 rotamers 32.70, 33.23, 33.54, 34.56, 36.05, 36.44, 36.58,
49.58, 49.98, 51.35, 113.38, 117.14, 125.74, 126.23, 126.72, 128.29, 128.40, 128.69, 129.25,
137.97, 138.94, 141.85, 147.39, 170.91, 171.11.
10. N-methyl-N-phenethyl-6-phenyl-3-(phenylamino)hexanamide (3.5). Scale: 5.0 mmol, yield:
1.56 g (78 %), pale yellow viscous oil, purity (cap. GC, after chromatography): 98 %.
IR (cm-1): (characteristic bands): 33342, 1632, 1602. 1H-NMR (): 
2 rotamers 1.42–1.79 (m),
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2.10 (dd, J1 = 6.4, J2 = 15.6), 2.29 (dd, J1 = 5.2, J2 = 15.6), 2.43 (dd, J1 = 4.0, J2 = 12.0), 2.54–2.62
(m), 2.66–2.80 (m), 2.74 (s, N–CH3), 2.89 (s, N–CH3), 3.40 (t, J = 7.6), 3.54 (td, Jd = 2, Jt = 7.2),
3.73–3.86 (m), 6.53–6.69 (m, Ar), 7.04–7.22 (m, Ar). 13C-NMR (ppm): 
2 rotamers 28.19, 33.23,
33.50, 34.56, 34.71, 35.60, 36.03, 36.64, 37.25, 49.60, 50.27, 51.33, 113.19, 117.02, 125.61, 126.19,
126.67, 128.18, 128.31, 128.65, 128.71, 129.22, 137.97, 138.96, 142.22, 147.37, 170.98, 171.18.
The typical procedure for the synthesis of the diamines 4.1–4.5 is illustrated for the diamine 4.3.
11. N-(5-methyl-1-(methyl(phenethyl)amino)hexan-3-yl)benzenamine (4.3). A three-necked
round-bottomed flask (100 mL) fitted with a thermometer, pressure-equalizing dropping funnel, and
a reflux condenser connected to an oil bubbler through a septum. The system was purged with Ar
and the flask charged with anh. THF (20 mL), a solution of 3.3 (1.0 g, 2.95 mmol/3 mL THF) and
NaBH4 (0.30 g, 7,8 mmol). As solution of BF3·Et2O (1.0 mL, 8.1 mmol/3 mL THF) was injected
into the dropping funnel and added dropwise to the stirred mixture (10 min at –5 ºC), the stirring was
continued for 1 h (< 0 ºC), then heated to reflux (1 h, 	65 ºC). After cooling (	20 ºC) the mixture was
treated successively with H2O (5 mL) and conc. HCl (10 mL, vigorous H2 evolution!), followed by
heating to reflux (30 min). After concentration (rotatory evaporator), the residue was dissolved in
H2O (5 mL) and alkalised (10 % NaOH, pH > 12). The liberated diamine 4.3 was extracted (CH2Cl2,
2  10 mL), dried (anh. K2CO3), filtered and the solvent removed. Yield: 0.86 g (90 %), pale yellow
viscous oil. Purity (cap. GC): 97 %. This product was without purification for the nex step.
IR (cm-1): (characteristic bands) 3393, 1602. 1H-NMR (): 0.88 (d, J = 6.6, CH3), 0.93 (d, J =
6.8, CH3), 1.30–1.46 (m), 1.63–1.72 (m), 2.39 (s, N–CH3), 2.61–2.75 (m), 2.81–2.86 (m), 3.42–3.55
(m), 6.54–6.68 (m, 3HAr), 7.08–7.15 (m, 7HAr). 13C-NMR (ppm): 22.69, 24.79, 31.46, 32.92,
41.54, 44.60, 49.51, 54.16, 58.98, 112.67, 116.48, 126.13, 128.37, 128.58, 129.20, 139.38, 147.98.
MS (CI): 325 (M+1, 100 %), 381 (M+57, 20 %).
The above procedure was used to synthesize the diamines 4.1, 4.2, 4.4, 4.5.
12. N-(4(methyl(phenethyl)amino)butan-2-yl)benzenamine (4.1). Scale: 5.0 mmol, yield: 1.23
g (87 %), viscous oil, purity (cap. GC): 97 %.
IR (cm-1): (characteristic bands) 3393, 1602. 1H-NMR (): 1.15 (d, J = 6.4, CH3), 1.63 (q, J =
6.4, CH2), 2.27 (s, N–CH3), 2.48 (t, J = 6.8, CH2), 2.53–2.62 (m, 1H), 2.70–2.80 (m, 3H), 3.49 (pr.s.,
1H), 4.03 (pr.s., 1H), 6.53 (d, J = 7.6, 2 o-HAr), 6.63 (t, J = 7.2, 1 p-HAr).
13C-NMR (ppm): 20.67,
33.74, 34.03, 42.01, 47.43, 54.66, 58.58, 112.94, 116.54, 125.85, 128.25, 128.58, 129.11, 140.30,
147.71. MS (CI): 191 (M-91, 25 %) 283 (M+1, 100 %).
13. N-(1-(methyl(phenethyl)amino)octan-3-yl)benzenamine (4.2). Scale: 5.0 mmol, yield:
1,59 g (94 %), viscous oil, purity (cap. GC): 96 %.
IR (cm-1): (characteristic bands) 3393, 1602. 1H-NMR (): 0.87 (t, J = 7.0, CH3), 1.28–1.37
(m), 1.44–1.52 (m), 1.55–1.62 (m), 1.72–1.78 (m), 2.29 (s, N–CH3), 2.47–2.65 (m), 2.72–2.81 (m),
3.38 (quint, J = 6.1, CH), 6.51–6.67 (3HAr), 7.08–7.17 (7HAr).
13C-NMR (ppm): 13.95, 22.54,
25.53, 31.85, 33.69, 34.87, 41.98, 51.82, 54.58, 59.54, 112.78, 116.37, 125.90, 128.29, 128.61,
129.15, 140.33, 148.18. MS (CI): 339 (M+1, 100 %), 395 (M+57, 20 %).
14. N-(1-methyl(phenethyl)amino)-5-phenylpentan-3-yl)benzenamine (4.4). Scale: 3.0 mmol,
yield: 1.03 g (92 %), viscous oil, purity (cap. GC) 97 %.
IR (cm-1): (characteristic bands) 3393, 1602. 1H-NMR (): 1.60–1.67 (m), 1.76–1.87 (m), 2.28
(N–CH3), 2.47–2.81 (m), 3.40–3.45 (m), 6.48–6.67 (m, 3HAr), 7.05–7.35 (m, 12HAr).
13C-NMR
(ppm): 31.79, 32.18, 33.61, 36.57, 41.87, 51.20, 54.45, 59.47, 112.81, 116.49, 125.69, 125.89,
128.25, 128.58, 129.12, 140.24, 141.96, 147.99. MS (CI): 373 (M+1, 100 %) 429 (M+57, 15 %).
15. N-(1-(methyl(phenethyl)amino)-6-phenylhexan-3yl)benzenamine (4.5). Scale: 3.5 mmol,
yield: 1.28 g (95 %), viscous oil, purity (cap. GC): 97 %.
IR (cm-1): (characteristic bands) 3393, 1602. 1H-NMR (): 1.47–1.78 (m, 6H), 2.27 (N–CH3),
2.47 (t, J = 7, CH2), 2.53–2.59 (m, 4H), 2.70–2.79 (m, 1H), 3.34–3.46 (m, 1H), 3.80 (pr. s, 1H),
6.49–6.62 (m, 3HAr), 7.07–7.29 (m, 12HAr).
13C-NMR (ppm): 27.69, 31.75, 33.55, 34.41, 35.78,
41.89, 51.03, 54.50, 59.46, 112.79, 116.47, 125.68, 125.95, 128.23, 128.32, 128.63, 129.19, 140.17,
142.21, 148.09. MS (CI): 387 (M+1, 100 %), 443 (M+57, 20 %).
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The typical procedure for the synthesis of the anilido-amines 5.1–5.5 is illustrated by the
anilido-amine 5.3.
16. N-(5-methyl-1-(methyl(phenethyl)amino)hexan-3-yl)-N-phenylpropionamide (5.3). A three-ne-
cked round-bottomed flask (50 mL) fitted with a thermometer, pressure-equalizing dropping funnel, and
a reflux condenser caped with a CaCl2-drying tube, was purged with Ar and the flask charged with
diamine 4.3 solution (0.70 g, 2.16 mmol/10 mL CH2Cl2) and Et3N (0.14 mL, 1.0 mmol), while the
propionyl chloride solution (	0.45 mL, 5 mmol/2 mL CH2Cl2) was added to the droping funnel. The
mixture was cooled (	0 ºC) and the chloride solution added dropwise (	10 min, 	0 ºC). The stirring was
continued (5 h, 0–20 ºC), whereupon the hydrochloride salt precipitate. MeOH (2 mL) was added (the
precipitate dissolves) and after 30 min of stirring the mixture was poured into NH4OH solution (25 %, 15
mL). The organic layer was washed with H2O (2  15 mL), dried (anh. K2CO3), filtered and concen-
trated (rotatory evaporator, 80 ºC, 30 min). The remaining reddish viscous oil was dissolved in dry Et2O
(15 mL) and added dropwise, with stirring to an anh. oxalic acid solution (0.25 g, 2.8 mmol/3 mL Et2O).
After cooling (	 20 ºC, 12 h), the precipitated monooxalate salt was collected by filtration, washed with
Et2O (5 mL) and vacuum dried. Yield: 1.06 g (90 %), white powder, m.p. (dec.): 99–100 ºC. The free
base was obtained by salt hydrolysis (10 %, NaOH, pH > 12) as a colourless oil. Purity (cap. GC) > 99 %.
The spectral data refere to the free base.
IR (cm-1): (characteristic bands): 1657, 1595. 1H-NMR (): 0.91 (d, J = 6.6, CH3), 0.98 (d, J =
6.6, CH3), 1.02 (t, J = 7.6, CH3), 1.07–1.14 (m), 1.26–1.38 (m), 1.44–1.74 (m), 1.93 (q, J = 7.4, CH2),
2.30 (s, N–CH3), 2.48–2.66 (m), 2.73–2.82 (m), 4.90–5.05 (m, CH), 7.05–7.45 (10 HAr).
13C-NMR
(ppm): 9.65, 22.55, 22.85, 24.86, 28.51, 31.43, 33.72, 42.20, 42.33, 51.23, 54.92, 59.72, 125.84,
128.03, 128.24, 128.58, 129.19, 130.02, 138.85, 140.37, 174.03. MS (CI): 381 (M+1, 100 %).
The above procedure was used to synthesize the anilido-amines 5.1, 5.2, 5.4, 5.5.
17. N-(4-(methyl(phenethyl)amino)butan-2-yl)-N-phenylpropionamide (5.1). Scale: 4.0 mmol,
yield (monooxalate salt): 1.62 g (95 %), white powder, m.p. (dec.): 115–117 ºC. Free base: colour-
less oil, purity (cap. GC): 97 %. The spectral data refer to the free base.
IR (cm-1): (characteristic bands): 1657, 1595. 1H-NMR (): 1.02 (t, J = 7.4, CH3), 	1.02 (CH3),
1.38–1.52 (m, 1H), 1.63–1.82 (m, 1H), 1.93 (q, J = 7.6, CH2), 2.29 (s, N–CH3), 2.42–2.65 (m, 4H),
2.72–2.82 (m, 2H), 4.92 (quint, J = 7.0, CH), 7.07–7.44 (m, 10 HAr).
13C-NMR (ppm): 9.29 (CH3),
18.90 (CH3), 28.12 (CH2), 32.42 (CH2), 33.34 (CH2), 41.73 (CH3), 48.38 (CH), 54.41 (CH2), 59.31
(CH2), 
125.47, 127.74, 127.87, 128.00, 128.24, 128.84, CHAr, 138.58 (CAr), 140.00 (CAr), 173.04
(C=O). MS (CI): 339 (M+1, 100 %).
18. N-(1-(methyl(phenethyl)amino)octan-3-yl)-N-phenylpropionamide (5.2). Scale: 3.5 mmol,
yield (monooxalate salt): 1.55 g (91 %), white powder, m.p. (dec.): 111–114 ºC. Free base: colour-
less oil, purity (cap. GC): > 97 %. The spectral data refer to the free base.
IR (cm-1): (characteristic bands): 1657, 1595. 1H-NMR (): 0.886 (t, J = 6.4, CH3), 1.02 (t, J =
7.6, CH3), 1.29–1.36 (m), 1.50–1.60 (m), 1.95 (q, J = 7.4, CH2), 2.29 (s, CH3), 2.48–2.62 (m),
2.72–2.82 (m), 4.74–4.88, 7.05–7.25 (m, 10HAr).
13C-NMR (ppm): 9.92, 13.59, 22.06, 25.92, 28.10,
30.75, 31.30, 32.83, 33.31, 41.76, 53.07, 54.46, 59.27, 125.39, 127.62, 127.80, 128.17, 128.80,
129.47, 138.69, 139.99, 173.54. MS (CI): 395 (M+1, 100 %).
19. N-(1-(methyl(phenethyl)amino)-5-phenylpentan-3-yl)-N-phenylpropionamide (5.4). Scale: 2.5
mmol, yield (monooxalate salt): 1.16 g (89 %), white powder, m.p. (dec.): 103–105 ºC. Free base:
colourless oil; purity (cap. GC): 97 %. The spectral data refer to the free base.
IR (cm-1): (characteristic bands): 1657, 1595. 1H-NMR (): 1.05 (t, J = 7.4, CH3), 1.55–1.79
(m, 4H), 1.99 (q, J = 7.8, CH2), 2.28 (s, N–CH3), 2.46–2.67 (m, 4H), 2.70–2.81 (m, 4H), 4.90–4.96
(m, CH), 7.13–7.43 (m, 15HAr).
13C-NMR (ppm): 9.64, 28.48, 31.12, 33.01, 33.60, 35.09, 42.10,
53.40, 54.70, 59.59, 125.70, 125.76, 128.14, 128.51, 129.25, 129.76, 138.92, 140.29, 141.72,
174.13. MS (CI): 337 (M-91, 20 %), 429 (M+1, 100 %).
20. N-(1-(methyl(phenethyl)amino)-6-phenylhexan-3-yl)-N-phenylpropionamide (5.5). Scale:
3.0 mmol, yield (monooxalate salt): 1.37 g (86 %), white powder, m.p. (dec.): 99–100 ºC. Free base:
colourless oil, purity (cap. GC): 97 %. The spectral data refer to the free base.
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IR (cm-1): (characteristic bands): 1657, 1595. 1H-NMR (): 1.01 (t, J = 7.6, CH3), 1.32–1.56
(m), 1.73 (quint, J = 7.2), 1.93 (q, J = 7.4, CH2), 2.27 (s, N–CH3), 2.44–2.66 (m), 2.70–2.80 (m),
4.78–4.95 (m, CH), 7.10–7.40 (m, 10HAr).
13C-NMR (ppm): 9.67, 28.47, 31.20, 32.50, 33.64, 35.51,
42.15, 53.03, 54.81, 59.64, 125.63, 125.81, 127.99, 128.20, 128.44, 128.56, 129.82, 138.78, 140.36,
142.11, 174.14. MS (CI): 443 (M+1, 100 %).
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Razvijen je efikasan postupak za dobijawe razli~itih acikli~nih 1,3-diamina, u
pet faza, i primewen u sintezi nove klase analoga fentanila otvorenog niza. Deri-
vati 5.1–5.5 (svi su nova jediwewa) sintetisani su sa ciqem da se proceni uticaj
piperidinskog prstena na opioidnoanalgeti~ku aktivnost anilido-piperidina. Po-
lazni -keto-amid 1.1, dobijen aminolizom metilacetoacetata metilfenetilaminom
(prinos 93 %), bio je sukcesivno tretiran sa NaH i BuLi, pri ~emu je postao veoma
reaktivni ,-dienolatni anjon 1.1a. Regio- i hemoselektivnim -alkilovawem ovog
dienolata razli~itim primarnim i sekundarnim alkil-halogenidima, dobijeni su
-keto-amidi 1.2–1.5 (prinos 76–91 %). Reduktivnim aminovawem keto-amida 1.1–1.5
pomo}u Zn praha i sir}etne kiseline, preko enaminskih intermedijera 2.1–2.5, po-
stali su -anilino-amidi 3.1–3.5 (prinos 74–85 %). Posle reduktivne deoksigenacije
tercijene amidne funkcije, koriste}i in situ generisani diboran, odgovaraju}i 1,3-di-
amini 4.1–4.5 izolovani su u prinosima 87–97 %. Sinteza ()-2,3-seco-fentanila 5.1–5.5
zavr{ena je N-acilovawem diamina 4.1–4.5 propionil-hloridom, a zatim talo`ewem u
obliku monooksalatnih soli (prinos 86–95 %). Na|eno je da je osnovno jediwewe,
2,3-seco fentanil 5.1, 40 puta slabiji narkoti~ki analgetik od fentanila, ali jo{
uvek 5–6 puta aktivniji od morfina u pacova, dok je i-Pr derivat 5.3 bio neaktivan.
Osim farmakolo{kog zna~aja, op{tim postupkom prikazanim u ovom radu, mogu se
sintetisati razli~iti 1,3-diamini, ukqu~uju}i i one sa funkcionalnim grupama. Ova
jediwewa mogu biti potencijalno zna~ajna kao kompleksiraju}i agensi i kao interme-
dijeri u sintezi aza-kraun-etara.
(Primqeno 24. maja 2004)
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